EIRGENIX RECEIVED THE ACCREDITATION CERTIFICATE OF FOREIGN DRUG MANUFACTURER FROM JAPAN
EirGenix is committed to the development of biosimilar drugs and CDMO (Contract Development and Manufacturing) service. We officially received the accreditation certificate of foreign drug manufacturer approved by the Ministry of Health, Labour, and Welfare in Japan.
This certificate of foreign drug manufacturer is classified as "Biological products", and its effective time is from October 31, 2017 to October 30, 2022, a period of five years.
Within the validity period in the future, EirGenix can bring our biological products manufactured in Taiwanese facility to Japan for sale. It is expected to substantially attract international pharmaceutical OEM orders, then Eirgenix's CDMO business will grow and go further into the international market.
2017-11-08
Related the latest news
EIRGENIX ACHIEVES THE FOURTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
2021/07/21
HONG HAI/FOXCONN FOUNDER TERRY GUO ANNOUNCES INVESTMENT TO ACCELERATE EIRGENIX’S GLOBAL EXPANSION
2021/04/06
POSITIVE PHASE III CLINICAL RESULTS FOR EIRGENIX'S PROPOSED TRASTUZUMAB BIOSIMILAR
2021/03/23
EIRGENIXは日本市場を拡大するために、日本の会社と長期供給契約の締結について
2021/03/02
VSTRIP® COVID-19 ANTIGEN RAPID TEST VALIDATED AND APPROVED IN INDIA!
2020/09/26
EIRGENIX ACHIEVES THE THIRD MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
2020/09/11
EIRGENIX RECEIVES 2020 BIOPROCESSING EXCELLENCE IN GREATER CHINA REGION AWARD!
2020/07/07
EIRGENIX ACHIEVES THE SECOND MILESTONE OF ITS BIOSIMILAR TRASTUZUMAB - LICENSING AGREEMENT
2020/03/09
EIRGENIX RECEIVES APPROVAL FROM JAPAN'S PMDA
2020/02/03
EIRGENIX COLLECTS ITS INITIAL SIGNING FEE DAYS BEFORE ITS OFFICIAL IPO
2019/06/27
EIRGENIX INC. ANNOUNCES 3-DAY STOCK OPTION BIDDING AHEAD OF ITS LATE-JUNE IPO
2019/06/10
EIRGENIX HOLDS ITS PRE-IPO PRESS CONFERENCE
2019/05/29
EIRGENIX SIGNS TRASTUZUMAB BIOSIMILAR LICENSE AGREEMENT WITH NOVARTIS SANDOZ
2019/04/30
EIRGENIX AWARDED FOR ITS INNOVATION AT THE NATIONAL INDUSTRIAL INNOVATION AWARDS
2019/04/10
EIRGENIX, INC. WINS BEST BIOPROCESS EXCELLENCE IN TAIWAN AWARD
2019/02/27
EIRGENIX, INC. OFFICIALLY OPENS ITS NEW WORLD-CLASS COMMERCIAL MASS PRODUCTION FACILITY
2019/01/23
EIRGENIX'S PHASE III CLINICAL TRIAL OF EG12014 HAS ENROLLED FIRST PATIENT
2018/10/30
CANCER THERAPEUTIC DRUG EG12014 IS APPROVED FOR PHASE III CLINICAL TRIAL
2018/05/22
EIRGENIX IS AWARD TOP 145 OF THE TECHNOLOGY FAST 500 COMPANIES IN ASIA PACIFIC (APAC)
2018/05/09
EIRGENIX RECEIVED "ASIA'S BEST CMO"
2018/01/31
EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" BEAM-RAISING CEREMONY
2017/10/19
CANCER THERAPEUTIC DRUG EG12014 PASSED THE DOUBLE-BLINDED PHASE I CLINICAL TRIAL
2017/05/02
EIRGENIX RECEIVED "GRAND WINNER OF BEST BIOPROCESS EXCELLENCE IN TAIWAN"
2017/02/16
EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" GROUNDBREAKING CEREMONY
2016/12/30
2015 TAIWAN BIO-MEDICAL AND NEW AGRICULTURAL INDUSTRY DRAFT COMPETITION AWARDS CEREMONY
2015/09/24
EIRGENIX AND FORMOSA LABORATORIES COLLABORATE TO ESTABLISH A PLATFORM FOR ADC CMC INTEGRATION SERVIC
2014/06/23
EIRGENIX DEVELOPS AND MANUFACTURES BIOLOGICS
2013/12/06
EG12014'S PHASE III CLINICAL TRIAL INTERIM RESULTS PUBLISHED AT SAN ANTONIO BREAST CANCER SYMPOSIUM
2021/12/08
BIOLOGICS LICENSE APPLICATION (BLA) SUBMITTED TO U.S FDA FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR
2021/12/18
MARKETING AUTHORIZATION APPLICATION (MAA) SUBMITTED FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR TO EMA
2021/12/21
EIRGENIX ACHIEVES THE FIFTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
2022/01/26
EIRGENIX COMPLETES NEOADJUVANT TREATMENT AND SURGERY FOR LAST PATIENT IN PHASE III CLINICAL TRIAL
2020/11/08
EirGenix Completed Its NTD 5.03 Billion Private Placement on the Fifteenth of October
2021/10/15
EIRGENIX'S REVENUE REACHES A RECORD HIGH IN JUNE
2019/07/10
EirGenix rated top 5% Corporate Governance Evaluation at TPEx after second year of the IPO
2022/05/04
EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives
2023/05/01